LONDON — The European Medicines Agency says it has begun an accelerated authorization process for an experimental coronavirus treatment made by GlaxoSmithKline and Vir BioTechnology.
In a statement on Friday, the EU drug regulator said it had started a rolling review of sotrovimab, based on early results from an ongoing study into whether the treatment can prevent hospitalization or death in people who don’t yet have severe COVID-19.
But EMA said it had not yet received the complete data and cautioned that “it is too early to draw any conclusions about the benefit-risk balance of the medication.” Although the EMA has given the green light to four vaccines, there are few licensed treatments for the coronavirus, especially any that might